Variables associated with RS survival by univariate analysis
| Characteristic . | HR . | LCI . | UCI . | P . | q . |
|---|---|---|---|---|---|
| Clinical feature | |||||
| Age > 60 y | 2.41 | 1.30 | 4.44 | .005* | .019* |
| Male | 0.69 | 0.40 | 1.21 | .199 | .412 |
| ECOG PS > 1 | 4.54 | 2.52 | 8.20 | < .001* | < .001* |
| Ann Arbor III-IV | 1.92 | 0.59 | 6.18 | .274 | .485 |
| Binet B-C | 1.97 | 0.95 | 4.10 | .068 | .174 |
| Extranodal sites > 1 | 1.28 | 0.71 | 2.30 | .403 | .579 |
| Tumor size > 5 cm | 2.62 | 1.45 | 4.71 | .001* | .006* |
| ALC ≥ 5.0 × 109/L | 1.17 | 0.67 | 2.03 | .579 | .699 |
| Platelet count < 100 × 109/L | 2.20 | 1.23 | 3.91 | .007* | .023* |
| LDH > 1.5 ULN | 2.52 | 1.41 | 4.48 | .002* | .009* |
| CD38 expression | 0.81 | 0.38 | 1.66 | .544 | .699 |
| ZAP70 expression | 1.31 | 0.46 | 3.75 | .604 | .699 |
| Prior therapies > 1 | 1.00 | 0.57 | 1.76 | .979 | .979 |
| Rituximab-containing regimen | 0.80 | 0.46 | 1.38 | .312 | .513 |
| Allogeneic stem cell transplantation | 0.19 | 0.04 | 0.78 | .027* | .078* |
| CR after RS induction treatment | 0.21 | 0.04 | 0.46 | < .001* | .001* |
| Pathologic feature | |||||
| CD5 expression | 1.12 | 0.65 | 1.93 | .669 | .699 |
| Non-GC phenotype | 1.30 | 0.40 | 4.18 | .659 | .699 |
| EBV infection | 2.84 | 0.84 | 9.60 | .091 | .209 |
| Molecular features | |||||
| TP53 disruption | 2.90 | 1.67 | 5.04 | < .001* | .001* |
| c-MYC aberrations | 1.20 | 0.59 | 2.43 | .612 | .699 |
| IGHV identity ≥ 98% | 1.29 | 0.72 | 2.34 | .384 | .579 |
| Stereotyped VH CDR3 | 1.41 | 0.81 | 2.46 | .215 | .412 |
| Characteristic . | HR . | LCI . | UCI . | P . | q . |
|---|---|---|---|---|---|
| Clinical feature | |||||
| Age > 60 y | 2.41 | 1.30 | 4.44 | .005* | .019* |
| Male | 0.69 | 0.40 | 1.21 | .199 | .412 |
| ECOG PS > 1 | 4.54 | 2.52 | 8.20 | < .001* | < .001* |
| Ann Arbor III-IV | 1.92 | 0.59 | 6.18 | .274 | .485 |
| Binet B-C | 1.97 | 0.95 | 4.10 | .068 | .174 |
| Extranodal sites > 1 | 1.28 | 0.71 | 2.30 | .403 | .579 |
| Tumor size > 5 cm | 2.62 | 1.45 | 4.71 | .001* | .006* |
| ALC ≥ 5.0 × 109/L | 1.17 | 0.67 | 2.03 | .579 | .699 |
| Platelet count < 100 × 109/L | 2.20 | 1.23 | 3.91 | .007* | .023* |
| LDH > 1.5 ULN | 2.52 | 1.41 | 4.48 | .002* | .009* |
| CD38 expression | 0.81 | 0.38 | 1.66 | .544 | .699 |
| ZAP70 expression | 1.31 | 0.46 | 3.75 | .604 | .699 |
| Prior therapies > 1 | 1.00 | 0.57 | 1.76 | .979 | .979 |
| Rituximab-containing regimen | 0.80 | 0.46 | 1.38 | .312 | .513 |
| Allogeneic stem cell transplantation | 0.19 | 0.04 | 0.78 | .027* | .078* |
| CR after RS induction treatment | 0.21 | 0.04 | 0.46 | < .001* | .001* |
| Pathologic feature | |||||
| CD5 expression | 1.12 | 0.65 | 1.93 | .669 | .699 |
| Non-GC phenotype | 1.30 | 0.40 | 4.18 | .659 | .699 |
| EBV infection | 2.84 | 0.84 | 9.60 | .091 | .209 |
| Molecular features | |||||
| TP53 disruption | 2.90 | 1.67 | 5.04 | < .001* | .001* |
| c-MYC aberrations | 1.20 | 0.59 | 2.43 | .612 | .699 |
| IGHV identity ≥ 98% | 1.29 | 0.72 | 2.34 | .384 | .579 |
| Stereotyped VH CDR3 | 1.41 | 0.81 | 2.46 | .215 | .412 |
HR indicates hazard ratio; LCI, 95% lower confidence interval; UCI, 95% upper confidence interval; ALC, absolute lymphocyte count; ULN, upper limit of normal; ZAP70, ζ-associated protein 70; CR, complete response; GC, germinal center; IGHV, immunoglobulin heavy chain variable region gene; and VH CDR3, immunoglobulin heavy chain complementarity-determining region 3.
Statistically significant.